Groupe Hospitalier Nord Essonne

Orsay 16 trials 10 recruiting

16 Registered trials

10 Currently recruiting

Organisation

Groupe Hospitalier Nord Essonne

Location

Orsay, France

Identifier

ORG-100047591

Address

ZAC De Corbeville, 1 Parvis De L Hopital, 91400, France

Departments

7021:Neurology
91160
CEA
Chir Dig
Département de neurologie
Digestive Oncology
Imagerie Médicale
Médecine nucléaire
Multi-purpose intensive care
Oncology
PSYCHIATRIE
Réanimation Médicale
réanimation polyvalente
Service de neurologie

Clinical trials at this site (16)

Search interface

The value of post-operative antibiotic therapy after laparoscopic appendectomy for complicated acute appendicitis (other than for generalize… Pending

2024-515834-34-00 complicated acute appendicitis 5
3-day intravenous antibiotic treatment versus 3-day intravenous followed by 7-day oral antibiotic treatment for acute pyelonephritis in chil… Pending

2024-518930-10-00 acute pyelonephritis (AP) in children 5
Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial Pending

2025-520573-39-00 Ultra High Risk of psychosis and first episode psychos 6
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc… Recruiting

2023-505486-92-00 Small bowel adenocarcinoma 4 2024-02-09
Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of … Recruiting

2024-512761-13-00 Remyelination in Multiple Sclerosis 5 2022-01-24
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
KISS Evaluation of early administration of Levetiracetam in the prevention and treatment of delirium during septic shock: a randomized, doub… Recruiting

2023-510449-51-00 Adult ICU patients with septic shock 5 2025-07-31
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized control… Recruiting

2023-507254-32-00 Severe hyponatremia and a high risk of rapid SNa overco 5 2024-12-17
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit Ended

2023-505108-52-00 Intensive Care 5 2023-12-20
[18F]-Fludarabine PET/MR Imaging for the Assessment of Newly-diagnosed Primary Central Nervous System (CNS) Lymphoma : a Pilot PET-MRI Study Ended

2024-512758-62-00 Patients with newly diagnosed primary central nervous s 9 2023-12-18